Bausch Health’s Salix spotlights liver disease indication for Xifaxan
21 Apr 2023
Drug Approval
Most people know Bausch Health’s Salix drug Xifaxan for its irritable bowel syndrome indication, thanks to consumer marketing efforts. But now SalixSalix is reminding people of its first approved indication for use in liver disease.
In a TV and digital ad campaign called “I Wish I Knew,” a real patient talks about his symptoms and diagnosis for overt hepatic encephalopathy (OHE). Hepatic encephalopathy is estimated to affect about 200,000 people with liver disease in the US, with up to 80% of people with cirrhosis developing some form of it. The brain condition is caused by a buildup of toxins the liver is unable to clear, and categorized as covert or overt depending on symptom severity. Xifaxan is approved for OHE.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.